Methamphetamine Abuse Clinical Trial
Official title:
Combating Craving With Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa
This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.
This study will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within frontostriatal circuitry from baseline to end of the 8-week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes and (2) to determine whether structural changes in frontostriatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT03226223 -
Pharmacogenetics of Naltrexone for Stimulant Abuse
|
Phase 2 | |
Not yet recruiting |
NCT05593796 -
Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder
|
N/A | |
Recruiting |
NCT04616625 -
Cardiovascular Effects of Prenatal Methamphetamine Exposure
|
||
Completed |
NCT04061941 -
Change in Cognitive Function in Stimulant Users
|
||
Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT05700994 -
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
|
N/A | |
Completed |
NCT04109014 -
FASTLANE II: Reducing Sex, Drug, and Mental Health Risk
|
N/A | |
Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT01822132 -
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
|
N/A | |
Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
Not yet recruiting |
NCT06233799 -
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
|
Phase 3 | |
Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A | |
Terminated |
NCT05034874 -
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
|
Phase 2 |